DC1

• CAT Number: I019742
• CAS Number: 169901-27-3
• Molecular Formula: C₃₄H₂₈ClN₅O₄S
• Molecular Weight: 638.14
• Purity: ≥95%
• Target: Cell Cycle/DNA Damage
• IUPAC Name: N-[2-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indole-3-carbonyl]-1H-indol-5-yl]-5-(3-sulfanylpropanoylamino)-1H-indole-2-carboxamide
• InChI: InChI=1S/C34H28ClN5O4S/c35-16-20-17-40(29-15-30(41)23-3-1-2-4-24(23)32(20)29)34(44)28-14-19-12-22(6-8-26(19)39-28)37-33(43)27-13-18-11-21(5-7-25(18)38-27)36-31(42)9-10-45/h1-8,11-15,20,38-39,41,45H,9-10,16-17H2,(H,36,42)(H,37,43)/t20-/m1/s1
• InChIKey: ZASLXALGERLDLT-HXUWFJFHSA-N
• SMILES: C1[C@H](C2=C(N1C(=O)C3=CC4=C(N3)C=CC(=C4)NC(=O)C5=CC6=C(N5)C=CC(=C6)NC(=O)CCS)C=C(C7=CC=CC=C72)O)CCl

DC1（Cat No.:I019742）is a small molecule that has been investigated for its potential therapeutic applications, particularly in the context of cancer research. It functions as a potent inhibitor of specific protein kinases involved in the regulation of cell growth, survival, and metastasis. DC1 is often studied in preclinical models for its ability to disrupt signaling pathways that drive tumor progression, including those related to the epidermal growth factor receptor (EGFR) or other kinases associated with cancer cell proliferation. Its precise mechanism of action and potential clinical applications are still under ongoing investigation.

Reference

[1]. Kovtun YV, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006 Mar 15;66(6):3214-21.